Morgan Stanley's price target implies that shares of Johnson & Johnson could rise another 17%.
Get this delivered to your inbox, and more info about our products and services.
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
Shares of J&J rose about 1% Tuesday, shaking off their premarket declines.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
JPMorgan sees shares of Procter & Gamble rising 11% from current levels.
JPMorgan's new price target implies that shares of Citigroup could rise 11% from here.
JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
